LIFR Antibody, HRP conjugated

The Leukemia Inhibitory Factor Receptor (LIFR) plays a multifaceted role in various biological processes, as evidenced by the following research findings:

• Angiogenesis in Colorectal Cancer: High LIFR levels in colorectal cancer promote endothelial cell proliferation and migration, increasing angiogenesis. This effect is partly mediated by IL-8. (PMID: 29751081)
• Adipogenesis Regulation: miR-377-3p suppresses adipogenesis in human bone marrow mesenchymal stem cells by targeting LIFR, revealing a novel mechanism of miRNA-mediated cellular differentiation. (PMID: 29959592)
• Association with Preeclampsia: High LIFR expression is associated with preeclampsia. (PMID: 29363569)
• Tumor Metastasis Suppression: LIFR attenuates tumor metastasis by suppressing YAP expression, suggesting its potential as a therapeutic target in clear cell renal cell carcinoma. (PMID: 29902078)
• Metastasis Regulation by lncRNA: The lncRNA CTD-2108O9.1 represses metastasis by targeting LIFR. (PMID: 29603493)
• Adenomyosis and Implantation: Reduced LIFR expression and subsequent signaling pathway activation suggest a mechanism by which LIF may affect the endometrium in patients with adenomyosis. (PMID: 27903796)
• Pancreatic Cancer Biomarker: LIFR, along with other proteins, exhibits aberrant glycan structures in the sera of pancreatic cancer patients, suggesting its potential as a diagnostic biomarker. (PMID: 28244758)
• Congenital Anomalies of the Kidney and Urinary Tract (CAKUT): Heterozygous LIFR mutations are found in CAKUT patients, highlighting LIFR's role in urogenital development. (PMID: 28334964)
• Beta-Catenin Inhibition: LIFR inhibits beta-catenin expression. (PMID: 27375070)
• RUNX1 Regulation: The LIFR gene is a direct target of RUNX1. (PMID: 26060100)
• Stuve-Wiedemann Syndrome: LIFR mutations are implicated in Stuve-Wiedemann syndrome. (PMID: 25868946)
• LIFR Glycosylation and Expression: The C65S mutant LIFR exhibits altered glycosylation and increased expression, potentially due to slower turnover. (PMID: 26285796)
• Melanoma Progression: High LIFR expression stimulates melanoma cell migration and correlates with poor prognosis. (PMID: 26329521)
• Adrenal Insufficiency: Stuve-Wiedemann syndrome patients with LIFR (p.Arg692X) mutations may develop adrenal insufficiency due to impaired LIF/LIFR signaling. (PMID: 25145448)
• Hepatocellular Carcinoma Metastasis: LIFR acts as a metastasis suppressor in hepatocellular carcinoma and serves as a prognostic biomarker. (PMID: 26249360)
• Hepatocarcinogenesis: LIFR plays a functional role in hepatocarcinogenesis. (PMID: 25749520)
• Multiple Sclerosis: Increased LIFR expression is observed on immune cells in multiple sclerosis patients. (PMID: 25514345)
• miR-155 Inhibition: The LIFRalpha-CT3 TAT fusion protein inhibits miR-155 expression. (PMID: 25092123)
• JAK/STAT3 Signaling: LIFR signaling typically follows the JAK/STAT3 pathway, initiated by various interleukin-6-type cytokines. (PMID: 24618404)
• CNTF Receptor Signaling: A R28E mutation in CNTF affects receptor signaling pathways. (PMID: 24802752)
• Colorectal Cancer Biomarker: LIFR rs3729740 and ANXA11 rs1049550 may serve as biomarkers for predicting sensitivity to targeted therapies in metastatic colorectal cancer. (PMID: 23579219)
• Herpes Simplex Encephalitis: CD118 deficiency (related to LIFR) may be associated with acute ventricle enlargement in a subset of herpes simplex encephalitis patients. (PMID: 23382563)
• Breast Cancer Tumor Suppression: LIFR functions as a tumor suppressor in breast cancer. (PMID: 22535017)
• Metastasis Suppression via Hippo-YAP Pathway: LIFR is a metastasis suppressor acting through the Hippo-YAP pathway and possesses prognostic value. (PMID: 23001183)
• Oncostatin M Binding: A unique loop structure in oncostatin M dictates its binding affinity to its receptor and LIFR. (PMID: 22829597)
• Schizophrenia: LIFR gene polymorphisms show association with schizophrenia and persecutory delusions. (PMID: 21971603)
• Endometrial Expression: LIF and LIFR are localized to decidual cells in the endometrium. (PMID: 21966484)
• Colon Cancer Inactivation: Decreased LIFR expression is a common inactivation event in colon cancer development. (PMID: 21617854)
• Hepatocellular Carcinoma: Downregulation of LIFR is associated with hepatocellular carcinoma. (PMID: 19733004)
• Schizophrenia and Working Memory: A LIF gene variant may contribute to hebephrenic schizophrenia and impaired working memory. (PMID: 19879916)
• LIF-R Gene and Protein Function: Review of LIF-R gene and protein structure, function, mRNA processing, and role in tumor cells. (PMID: 11042511)
• LIF Receptor Complex: The upper cytokine-binding module and Ig-like domain of LIFR are essential for a functional LIF receptor complex. (PMID: 11812136)
• Glycoprotein 190 (gp190): Separate functions for the two modules of the membrane-proximal cytokine binding domain of gp190 in ligand binding and receptor activation. (PMID: 11834739)
• CNTFR interactions: In vitro interactions of CNTFR with LIFR and gp130. (PMID: 12707266)
• LIFR Mutations and mRNA Stability: Mutations affecting LIFR mRNA stability, leading to protein absence and impaired JAK/STAT3 signaling. (PMID: 14740318)
• Primordial Follicle Growth: LIF and its receptor may be involved in the growth initiation of human primordial follicles. (PMID: 15044601)
• Ciliary Neurotrophic Factor Signaling: Deletion of the N-terminal cytokine binding domain in a LIFR mutant abolishes ciliary neurotrophic factor signaling. (PMID: 16051226)
• Embryonic Stem Cell Differentiation: LIF and LIFR expression increases during human embryonic stem cell differentiation. (PMID: 16949591)
• Soluble Oncostatin M Receptor (sOSMR): sOSMR neutralizes OSM and interleukin-31 properties. (PMID: 17028186)
• Quaternary Cytokine Receptor Complex: Biophysical and structural characterization of a quaternary cytokine receptor complex involving gp130, LIF-R, CNTF, and CNTF-Ralpha. (PMID: 18775332)

HGNC: 6597

OMIM: 151443

KEGG: hsa:3977

STRING: 9606.ENSP00000263409

UniGene: Hs.133421